MIF/CD74 axis is a target for novel therapies in colon carcinomatosis by unknown
Bozzi et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:16 
DOI 10.1186/s13046-016-0475-zRESEARCH Open AccessMIF/CD74 axis is a target for novel
therapies in colon carcinomatosis
Fabio Bozzi1†, Angela Mogavero2,3†, Luca Varinelli4†, Antonino Belfiore1, Giacomo Manenti5, Claudio Caccia6,
Chiara C. Volpi1, Galina V. Beznoussenko7, Massimo Milione1, Valerio Leoni6, Annunziata Gloghini1,
Alexandre A. Mironov7, Ermanno Leo8, Silvana Pilotti1, Marco A. Pierotti3, Italia Bongarzone4*
and Manuela Gariboldi2,3Abstract
Background: Strategies aimed at obtaining a complete cytoreduction are needed to improve long-term survival for
patients with colorectal cancer peritoneal carcinomatosis (CRC-pc).
Methods: We established organoid models from peritoneal metastases of two naïve CRC patients. A standard
paraffin inclusion was conducted to compare their 3D structure and immunohistochemical profile with that of the
corresponding surgical samples. RNA expression levels of the CRC stem cell marker LGR5 was measured by in situ
hybridization. The secretome of organoids was profiled by mass spectrometry. Energy homeostasis of organoids was
interfered with 4-IPP and metformin. Biochemical and metabolic changes after drug treatments were investigated by
western blot and mass spectrometry. Mitochondria impairment was evaluated by electron microscopy and mitotraker
staining.
Results: The two organoids recapitulated their corresponding clinical samples in terms of 3D structure and
immmunoistochemical profile and were positive for the cancer stem cells marker LGR5. Proteomic analyses of
organoids highlighted their strong dependence on energy producing pathways, which suggest that their targeting
could be an effective therapeutic approach.
To test this hypothesis, we treated organoids with two drugs that target metabolism acting on AMP-activated protein
kinase (AMPK), the main regulator of cellular energy homeostasis, which may act as metabolic tumour suppressor in
CRC. Organoids were treated with 4-IPP, an inhibitor of MIF/CD74 signalling axis which activates AMPK function, or
metformin that inhibits mitochondrial respiratory chain complex I.
As a new finding we observed that treatment with 4-IPP downregulated AMPK signalling activity, reduced AKT
phosphorylation and activated a JNK-mediated stress-signalling response, thus generating mitochondrial impairment
and cell death. Metformin treatment enhanced AMPK activation, decreasing the activity of the anabolic factors
ribosomal protein S6 and p4EBP-1 and inducing mitochondrial depolarization.
Conclusion: We provide evidence that the modulation of AMPK activity may be a strategy for targeting metabolism of
CRC-pc organoids.
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Intraperitoneal dissemination is a common progression
feature for colorectal cancer (CRC). For the past two de-
cades, aggressive treatments of CRC peritoneal carcin-
omatosis (CRC-pc), such as cytoreductive surgery plus
hyperthermic intraperitoneal chemotherapy, has im-
proved long-term survival [1]. However, the majority of
cases present widespread metastases which cannot be
destroyed by systemic chemotherapy; therefore, the de-
velopment of new strategies to prevent the progression
of metastatic disease is imperative.
Tumour-initiating, or cancer stem cells (CSCs), have a
key role in metastatic CRC (hepatic and/or lung) and
chemotherapy resistance [2]; however, limited informa-
tion is known about the role of CSCs in CRC-pc devel-
opment. The first step towards the identification of new
therapeutic alternatives requires the development of
dedicated pre-clinical models that in vitro and in vivo
recapitulate the biological features of CRC-pc.
Past years have seen unprecedented developments of
three-dimensional (3D) cultures called cancer organoids.
A CRC organoid is obtained by allowing cells (derived
from a primary tumour specimen) to self-organize into a
3D structure that recapitulates the original glandular
organization commonly observed in human CRC surgi-
cal samples. Organoids grow as irregular compact struc-
tures, and can be expanded indefinitely and represent
the physiology of native tumours much better than trad-
itional cell lines [3]. We have established (in serum-free
medium) two CRC-pc organoid cultures of peritoneal
metastatic lesions from two CRC patients that showed
enrichment in the expression of the CRC CSC marker
leucine-rich repeat containing G protein-coupled recep-
tor 5 (LGR5) a member of the canonical WNT pathway
and a well-recognized marker of the cell progenitor
population located at the crypt-base [4, 5].
In this study, we hypothesized that CRC organoids may
secrete a variety of growth factors, cytokines, proangiogenic
factors, exosomes, and even extracellular matrix compo-
nents, some of which are fundamental for maintaining self-
renewal and proliferative capacity. Using the advantageous
properties of “serum-free” growth conditions for both orga-
noids, we searched for factors with potential therapeutic
relevance in their “secretome” compartment produced dur-
ing cell culture [6]. We found the prominent expression of
metabolic pathways mainly related to oxidative homeostasis
and glucose metabolism and focused on the macrophage
migration inhibitory factor (MIF)/CD74/mitochondria axis,
and on the relative 4-iodo-6-phenylpyrimidine (4-IPP) in-
hibitor, as playing an important role in JNK modulation of
the cellular response to reactive oxygen species [7]. To fur-
ther examine the importance of targeting metabolism in
organoids, we studied the effects of direct perturbation of
mitochondrial integrity using metformin, which inhibitsrespiratory-chain complex I, thus inducing a pro-cell death
decline in energy status.
Methods
Cell culture and tissue samples
Two cancer organoids (CRC-pc1 and CRC-pc2, herein-
after referred to as C1 and C2) were established from
peritoneal metastases of naïve patients with stage IV,
grade 2 (C1) and grade 3 (C2) CRC following protocols
and conditions published by Sato T et al. [8]. BRAF and
KRAS mutation patterns in organoids reflected those in
the original tumours. Formalin fixed paraffin embedded
(FFPE) tissue samples obtained from additional CRC-pc
patients (C3, C4 and C5) were included in the study for
validation experiments.
The two organoids were maintained in F-12 medium
(DMEM F12, Gibco, Carlsbad, CA, USA) as previously
described [8].
This study was approved by the Institutional Review
Board of Fondazione IRCCS Istituto Nazionale dei Tumori
and each patient provided written informed consent to
donate remaining tissues after diagnostic procedures.
Morphology and immunohistochemistry
A standard paraffin inclusion of both organoids was con-
ducted to compare their 3D structure and immunohisto-
chemical profile with those of the corresponding surgical
samples. Immunohistochemistry was done with 3-μm FFPE
tissue sections. The antibodies used for immunohistochem-
istry analyses are listed in Additional file 1: Table S1.
In Situ Hybridization (ISH)
ISH for LGR5 RNA expression was manually performed
using the RNAscope 2.0 High Definition detection kit
(Brown) (Advanced Cell Diagnostics, Inc., Hayward, CA)
assay according to the manufacturer’s instructions.
Briefly, 5 μm FFPE tissue sections were incubated with
Pretreat buffers 1, 2 and with Pretreat Buffer 3 at 40 °C.
Slides were hybridized with probes of interest for 2 h at
40 °C, followed by incubations with amplifier reagents
1–6, color development with 3, 3′- diaminobenzine
(DAB) and counterstaining with haemotoxylin. RNA-
scope probes used were LGR5 (311021), the negative
control bacterial DapB (310043) and endogenous UBC
(310041), used as positive control. Positive staining sig-
nals were identified as brown punctuate dots present in
the cytoplasm and/or nucleus [9].
Nano-scale liquid chromatographic tandem mass
spectrometry (nLC-MS/MS) analysis
Proteins secreted in the medium (secretome) by C2
organoids were collected and the secretome was profiled
as previously described [10].
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The Search Tool for the Retrieval of INteracting Genes/
proteins (STRING) database [11] (9.1 version (Database
issue):D412-416) was used for prediction of protein
subcellular localization. Resulting proteins were also ana-
lysed using PANTHER (Protein ANalysis THrough Evolu-
tionary Relationships) system (http://www.pantherdb.org)
[12]. Network analyses were performed using the Ingenuity
Pathways Analysis (Ingenuity Systems) software.
Sample preparation, SDS-PAGE and immunoblotting
Organoids were cultured for 18 h, and exposed to
drugs for the times indicated. Cell pellets were solubi-
lized as previously described [13]. Protein concentra-
tions, SDS-PAGE and electroblotting were determined
and performed as previously described [14]. The anti-
bodies used for western blotting analyses are listed in
Additional file 1: Table S2.
Trypan blue exclusion
A standard trypan blue exclusion assay was used to
evaluate cell viability after 4-IPP and metformin treat-
ments. Data were analyzed using Student’s t-test.
Drug treatments
For cell treatments, 88.5 mM of 4-iodo-6-phenylpyrimidine
(4-IPP) (Calbiochem, Milan, Italy) and 1 M metformin
(Sigma-Aldrich, St. Louis, MO, USA) in 100% DMSO and
in PBS 1×, respectively, were diluted directly in the cell cul-
ture medium to achieve the working concentrations. The
final solvent and vehicle concentrations were less than 0.1%
for all samples, including controls.
Isotope dilution mass spectrometry analysis
C2 organoids were treated with 50 or 100 μM 4-IPP and
5 mM metformin. After 24 h, treated cells were lysed
and the lysates were analysed by isotope dilution mass
spectrometry, as previously described [15].
Reactive oxygen species detection
C2 organoids were seeded into a 96-well plate. After 24 h,
cells were treated with 5 mM metformin for 120 h and
with 100 μM 4-IPP for 6 h. Extracellular H2O2 formation
was detected and quantified using the ROS-Glo H2O2
assay (Promega, Madison, WI, USA) according to instruc-
tions provided by the manufacturer. Luminescence inten-
sity was quantified using a microplate reader (Infinite 200,
TECAN Group, Ltd., Männedorf, Switzerland).
Mitochondrial membrane potential analysis
Mitochondrial membrane potential of cells was detected
using a MitoProbe™ JC-1 Assay Kit for flow cytometry
(Thermo Fisher Scientific Corporation, Carlsbad, CA,
USA) after treatment with drugs for the times indicated.Flow cytometry analyses were performed as previously
described [16].
Electron microscopy
Cells were fixed by addition of 2.5% glutaraldehyde in
0.1 M cacodylate buffer (pH 7.2) for 2 h [17]. Next, sam-
ples were post-fixed with reduced OsO4 for 1 h [18].
Osmium staining was treated with 0.3% thiocarbohydra-
zide in O.2 M cacodylate buffer (pH 6.9) for 30 min
[19]. Finally, cells were treated with the reduced OsO4
for 1 h in the darkness and placed 50% ethanol, which
was gradually replaced by 70, 90 and 100% ethanol. After
this dehydratation, samples were embedded in Epon
[19]. After 24-h polymerization at 60 °C, samples were
cut using Leica FC6 ultramicrotome (Leica, Wien,
Austria) and examined in Tecnai 20 transmission elec-
tron microscope (FEI, Endhoven, The Netherland) [20].
Mitotracker staining and confocal microscopy
C2 cells were plated in 100 mm Petri dishes (2 × 106 cells/
well), incubated for 18 h before treatment with 50 or
100 μM 4-IPP (24 h) or with 5 mM metformin (120 h).
The cells were stained with MitoTracker Deep Red FM
(Molecular Probes, Invitrogen, Carlsbad, CA, USA) at a
final concentration of 60 nM, then fixed with 4% parafor-
maldehyde at 37 °C for 15 min, and washed with
phosphate-buffered saline. Immunofluorescence staining
was performed on 2-μm paraffin-embedded sections,
deparaffinised in xylene and rehydrated in graded alco-
hols. The slides were washed in 0.05 M phosphate-
buffered saline, incubated with DAPI 1:35,000 (Molecular
Probes) for 10 min, washed again in 0.05 M phosphate-
buffered saline and then fixed using Prolong Antifade
(Molecular Probes). Confocal laser scanning microscopy
was performed using the Leica TCS SP8 X microscope
(Leica Microsystems GmbH, Mannheim, Germany).
Results
3D structures, IHC profile and LGR5 expression of the
organoids
In-phase contrast microscopy showed both tubular-
branched and more round shaped 3D structures present
in C1, while C2 was mainly composed of round-shaped
cellular aggregates (Additional file 2: Figure S1).
After paraffin inclusion, C1 organoids exhibited glan-
dular structures lined by pseudostratified columnar cells
with central fibrinoid core and dirty necrosis along with
roundish solid aggregates of not aligned tumour cells.
These features mirrored those present in the corre-
sponding histologic sample (Fig. 1a). In C2 organoids
the cells exhibited adhesion loss and were organized in
ring and/or ribbon-like structures. The corresponding
sample showed solid nests of poorly differentiated cells
with eosinophilic cytoplasm surrounded by desmoplastic
Fig. 1 Immunohistochemical profile of FFPE sections from C1 and C2 organoids and corresponding surgical samples. Haematoxylin and eosin
(H&E) staining and CK AE1/AE3, CK19, CK20, CDX2 and Ki67 immunostaining of C1 a and C2 b. Arrows indicate the weak CK20 staining of C2
organoids and of the corresponding surgical sample. Magnifications at 20X
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expressed Cytokeratins (CK) A1-A3, −19, −20 (Fig. 1) and
Claudin 4, and were negative for CK7 and Paired Box 8
(PAX8) (data not shown). C1 retained a high expression of
Caudal Type Homeobox 2 (CDX2) compared to C2.
Finally, according to the observed rapid growth, both
organoids had a very high Ki-67 staining (Mib1) (Fig. 1).
By ISH, we investigated the expression of LRG5, the
marker of the cell progenitor population located at the
crypt-base [4, 5]. LRG5 RNA expression was observed in
both organoids (Fig. 2). C1 displayed a gradient of LRG5
staining that was stronger in the peripheral sheet of epi-
thelial cells compared to more luminal sheets. Conversely,
C2 LGR5 was very focally expressed by some apical and
peripheral organoid cells, resulting in a more heteroge-
neus staining. Transcription of LGR5 was also confirmed
in their corresponding clinical FFPE materials (Fig. 2).
Taking advantage from the serum-free growth condi-
tions of CRC-pc organoids, we profiled the secretome
compartment to search for novel molecular candidates for
therapy involved in CRC-pc development and coupled it
with a classical pharmacological approach aimed at ex-
ploring the possible implications of these candidates in
CRC-pc. Indeed, we also used C1 organoids for validating
the results obtained from the use of C2.
We stated that these proteins playing a role in crucial
biological processes were secreted by organoids and that
they were present also in clinical samples. These studiessupport the concept that CRC-pc organoids may consti-
tute a pre-clinical model for investigating the biology of
CRC-derived peritoneal lesions.
Over-represented biological processes identified by
secretome in C2 organoids
The secretome composition of C2 organoids was investi-
gated using a classical bottom-up proteomic analysis with
LC-Orbitrap mass spectrometry. Of the 229 items, 191
(83%) were recognized as proteins with GO extracellular
space by STRING (Fig. 3a). PANTHER assessed overrep-
resentation of proteins involved in Parkinson disease, gly-
colysis and pentose phosphate pathways (Fig. 3b). These
results are consistent with the previous observation that
functions related to glucose metabolism and mitochondria
homeostasis are downregulated in neurodegeneration,
including Parkinson’s disease (PD), but upregulated in
colorectal cancer [21].
Analysis of the secreted proteins with annotations in the
IPA database identified networks that were enriched in pro-
teins involved in metabolism homeostasis, protein ubiquiti-
nation, cell cycle and DNA repair, and were significantly
over-represented in cancer (Additional file 2: Figure S2).
Macrophage migration inhibitory factor (MIF)/CD74
signalling axis
Secretome composition of C2 organoids included pro-
teins potentially able to mediate high metabolic demand,
Fig. 2 In situ hybridization. in situ hybridization of LGR5 on FFPE sections of C1 and C2 organoids, and of the surgical specimens from which
they originated
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ance. One of them was the multifunctional cytokine MIF
(Fig. 3c), the ligand of CD74 receptor. MIF/CD74 axis
can promote cell survival by modulating glucose uptake
and metabolism through the activation of AKT and
AMPK proteins and is considered a potential target for
therapy [22] (Fig. 3c).
MIF and CD74 were expressed in C2 organoids and in
the corresponding tumour tissue (Fig. 4a and b). We
then characterized key molecules involved in the
downstream-signalling cascade of the MIF/CD74 com-
plex. As expected C2 organoids exhibited AKT- and
AMPK-specific phosphorylation (respectively at posi-
tions S473 and T172, Fig. 4a) and suppression of JNK
activity due to MIF mediated inhibition of JAB1 (data
not shown).
Since MIF/CD74 axis through AMPK activation acceler-
ates glucose uptake, which enhances mitochondrial func-
tions [23], we assessed whether the MIF/CD74 axis
supports and maintains high levels of metabolism of C2
organoids. We have recently observed an extensive alter-
ation of some crucial oncogenic signals and a decrease in
Krebs cycle activity through the specific inhibition of MIF
activity using 4-IPP in papillary and anaplastic thyroids
carcinoma models [24]. In the work we demonstrated by
MALDI-TOF analysis that 4-IPP can effectively recognize
MIF as its target.
We expect that targeting MIF/CD74 axis in CRC-pc
models could give similar results inducing a strong im-
pairment in many crucial metabolic pathways and leading
to a dramatic change of the homeostasis of colonic carcin-
omatosis. Conversely, we examined the effects of AMPKstimulation by using metformin, an AMPK activator that
disrupts mitochondrial functions through inactivating
mitochondrial respiratory chain complex I [25].
Cellular and signalling effects of 4-IPP and Metformin on
C2 organoids
We evaluated the 4-IPP effects by targeting C2 orga-
noids with various concentrations of inhibitor (10, 25,
50, 100 μM). Twenty-four hours after treatment with 4-
IPP, C2 organoids appeared disaggregated (Fig. 4c left)
and died within 48 h. The disaggregation of organoids
was also observed after treatment with metformin that,
on the other hand, induced only a slight increase of cell
death after 120 h (Trypan blue assay, Fig. 4d).
Treatment with 50 and 100 μM 4-IPP activated ERK
phosphorylation. In contrast, AKT and AMPK phosphor-
ylation was abrogated (Fig. 4e). The decreased phosphor-
ylation of the AKT-specific phosphorylation site on
FOXO3 further demonstrated the suppression of AKT ac-
tivity and possibly supported the impairment of C2 viabil-
ity. Shorter 4-IPP treatments (3, 6 and 12 h) exhibited
similar results (Additional file 2: Figure S3). Treatment of
C2 organoids with metformin inhibited phosphorylation
of mTOR, ribosome protein S6 and 4E-BP1 but did not
inhibit ERK and AKT (Fig. 4f). Treatments with 4-IPP in-
creased the activity of the stress-activated protein kinase,
JNK, in a dose-dependent manner, explainable by the acti-
vation of a complete stress-related response (Fig. 4e). In
parallel, a dramatic change in the anti-phosphotyrosine/
phosphothreonine profile was observed probably due to
inhibited phosphatase activities (Fig. 4g, left panel). In-
deed, PP2A phosphorylation was switched off after 4-IPP
Fig. 3 Over-represented Gene Ontologies and pathways in the secretome of C2 organoids. a Gene Ontology analysis of secreted proteins. The
Search Tool for the Retrieval of INteracting Genes/proteins (STRING) database was used for prediction of protein subcellular localization. STRING
confidence score represented the probability of finding functional modules that were selected if the significance (p-value) of GO enrichment was
less than 0.01. Statistical significance was ascertained with a false discovery rate (FDR) threshold of <0.05. b PANTHER overrepresentation test.
Proteins involved in metabolic process and regulation of extracellular activities were also major components of the C2 secretome. The table
shows the most representative identified overrepresented categories of proteins involved in Parkinson disease, glycolysis and pentose phosphate
pathways. Experiments were performed in duplicate. Data were considerate significant when p≤ 0.05. c Network analysis was performed using
Ingenuity Pathway Analysis software. The analysis shows the connection between the MIF, DDT (MIF-2) with AMPK embedded within the
network. The network predicts the potential value and validity of the MIF-AMPK connection. d Summary of the modulation of AMPK activity on
organoids through MIF
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treatment did not significantly modify phosphotyrosine/
phosphothreonine profiles and phosphorylation of PP2A
and PPP1A (Fig. 4g, and h, right panels).
These results suggested that inhibition of AKT and
AMPK-related pathways has more pronounced effects in
terms of cell survival and stress-related response rather
than the implementation of AMPK/mTOR/S6/4EBP1
axis (Fig. 4i).
Metabolic changes after 4-IPP and metformin treatments
To investigate the metabolic effects of the two drugs, we
analysed the cellular amount of some metabolites involvedin glycolysis, tricarboxylic acid (TCA) cycle, fatty acids
(FAs) and cholesterol synthesis in lysates from C2 orga-
noids after 4-IPP and metformin treatments by isotope-
dilution gas chromatography-mass spectrometry (GC-MS)
analysis [15]. After 4-IPP treatment, glycerol-3-phosphate
and pyruvate were elevated and citrate, fumarate, malate
and succinate were reduced (Fig. 5 and Additional file 1:
Table S3). Conversely, after metformin treatment, lactic
acid and glycerol-3-phosphate were elevated and pyruvate,
succinate, fumarate, malate and citrate were reduced. 4-IPP
treated C2 organoids showed a moderate reduction in fatty
acids and cholesterol synthesis, while exposure to metfor-
min resulted in reduced fatty acid levels and cholesterol
Fig. 4 (See legend on next page.)
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Fig. 4 Effects of 4-IPP and metformin on C2 organoids. a MIF/CD74 signaling in C2 organoids. Lysates from C2 organoids expressed MIF, CD74
and presented activated AKT and AMPK. b Hematoxylin eosin and immunohistochemical staining of C2 tumour sample with anti-MIF and anti-CD74
antibodies. Magnifications at 10X. c Micrographs of C2 organoids before and after drug treatments. 4-IPP and metformin treatments induced a marked
morphological change in C2 organoids, resulting in a loss of their original spheroid organization. Magnifications: 10X. Scale bars = 50 μm. d C2
organoids were treated with 5 mM metformin for 120 h or 50 and 100 μM 4-IPP for 24 and 48 h. The percentage of cell death was determined by trypan
blue exclusion assay. Data are expressed as the mean ± SD. *P< 0.01 compared with untreated control and 50 μM 4-IPP. **P< 0.01 compared with
untreated control and 100 μM 4-IPP. We have not observed significant increase in the percentage of cell death after metformin treatments compared with
untreated controls. All the experiments were replicated at least three times. e Immunoblots of the principal proteins involved in CD74/MIF pathway. C2
organoids were untreated or treated with 50 and 100 μM 4-IPP for 24 h; lysates were resolved by 4–12% SDS–PAGE and immunoblotted. f Immunoblots
of the principal proteins involved in metformin pathway. C2 organoids were untreated or treated with 5 mM metformin for 120 h; lysates were
resolved by 4–12% SDS–PAGE and immunoblotted. g Global tyrosine and threonine phosphorylation changes in C2 organoids after 4-IPP and
metformin treatments. C2 organoids were untreated or treated with 50 and 100 μM 4-IPP for 24 h and with 5 mM metformin for 120 h; lysates
were resolved by 4–12% SDS–PAGE and immunoblotted. h Immunoblots showing the expression and activity of the PP2A and PP1 proteins
before and after 4-IPP or metformin treatments. Blots are representative of the results from multiple (at least two) experiments. i Observed
consequences of the 4-IPP or metformin treatments on C2 organoids
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cells treated with 4-IPP (Fig. 5 and Additional file 1:
Table S3). Metformin treatment reduced cholesterol syn-
thesis (measured as the cellular amount of cholesterol pre-
cursor lathosterol, lanosterol and desmosterol), as well as
the amount of cholesterol and membrane fatty acids which
are part of phospholipids, structural molecule of the lipid
bilayer. It is likely that the alterations to the cholesterol and
fatty acid metabolism may be both the consequence as well
as a mechanism to induce the mitochondrial dysfunction in
tumour cells exposed to metformin. Moreover the increase
of pyruvate followed by the strong impairment in the pro-
duction of the principal metabolites involved in the TCAFig. 5 Metabolic changes after 4-IPP or metformin treatments. The figu
mass spectrometry after C2 treatments with 4-IPP at 100 μM for 24 h
proteins and are normalized to the value of total proteins present in each sam
Metabolites values are also plotted; blue bars mark the amount with respect t
cycle (citrate, succinate and fumarate) were reduced both in 4-IPP and m
was a significant increase in lactate production, suggestive of an inefficie
Citrate released by mitochondria is converted into Acetyl-CoA, NADPH and ATP
sterols (markers of cholesterol synthesis) were reduced in both 4-IPP and metfo
both treatmentscycle in C2 organoids after 4-IPP treatment seems to be re-
lated to a mitochondria disruption provoked by the knock
down of MIF activity.
Mitochondria impairment after 4-IPP and metformin
treatments in C2 organoids
Because mitochondria are known to produce significant
amounts of ROS that may generate oxidative stress contrib-
uting to mitochondrial damage, affecting signal transduc-
tion pathways, cellular functions and viability, we studied
the effects of the two compounds on ROS production
(Fig. 6a). ROS-H2O2-Glo assay showed an increase of ROS
production in C2 organoids after metformin and 4-IPPre shows the bargraphs relative of the metabolites analysed by
and metformin at 5 mM for 120 h. Values are expressed as ng/mg
ple. Each value represents the mean of five independent replicates.
o the highest values. Metabolic organic acids intermediates of the TCA
etformin treated cells. In the case of metformin treated cells, there
nt pyruvate-dehidrogenase activity due to impaired TCA and OXPHOS.
for lipid (cholesterol and fatty acids) synthesis. Cholesterol and precursor
rmin treated cells. Very long chain fatty acids (>C16) were reduced by
Fig. 6 Mitochondria impairment after 4-IPP and metformin treatments in C2 organoids. a Reactive oxygen species detection with ROS-H2O2-Glo
assay kit. C2 cells were treated with metformin 5 mM, 4-IPP 100 μM or left untreated for 120 and 24 h respectively. Extracellular H2O2 formation was
detected and quantified using the ROS-H2O2-Glo assay. Luminescence intensity was quantified using a microplate reader with a 500 ms integration
time, reported as relative light units and normalised to 0 cells/well treatment conditions. Standard deviation was calculated for a set of triplicate values.
b Confocal microscopy images of mitochondria using Mitotracker® Deep Red FM in C2 cells untreated (A2; D1; E1), treated with 50 μM 4-IPP for 24 h
(B2), 100 μM 4-IPP for 24 h (C2), or 5 mM metformin for 120 h (D2; E2). Arrows indicate aggregated mitochondria. 4-IPP treatment leads
to mitochondria impairment in C2 cells. Metformin treatment reduces signal intensity of Mitotracker (asterisk) suggesting a depolarization
of mitochondrial membrane potential. The figure shows data from a representative experiment. DIC: differential interference contrast. Magnifications: 10X.
Scale bars = 50 μm. All the experiments were replicated at least three times. C Flow cytometry analysis of the mitochondrial membrane
potential using JC-1 assay on C2 organoids treated with metformin for 120 h or left untreated. Staining JC-1 revealed that metformin treatment caused a
significant increase in the amount of FITC aggregates, a pattern that is characteristic for disruption of mitochondrial membrane potential.
d The ultrastructure of the C2 cells after 4-IPP (D1-3) or metformin treatment (D4-6) and left untreated (D7). The white arrows show autophagic structures
and red stars indicate apoptotic bodies present in 4-IPP treated cells. White triangles show irregular mitochondria, blue stars lipid droplets and the yellow
star a multilamellar structure present in metformin treated cells. Additionally, no signs of autophagy, apoptosis or irregular mitochondria were observed in
untreated cells (D7). e Functional consequences of 4-IPP or metformin treatments on C2 organoids
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noids undergo genotoxic stress due to rising levels of ROS.
A mitochondrial-targeted probe which accumulates in
mitochondria, depending on their membrane potential,
was used to morphologically explore the mitochondrial
network in C2 organoids under 4-IPP and metformin in-
hibition. Briefly, we monitored the mitochondrial mem-
brane potential using JC1 probe, a cationic carbocyanine
fluorescent dye that exhibits a potential-dependent accu-
mulation in mitochondria: a fluorescent emission shift fromgreen (~525 nm) to red (~590 nm) indicates increase of the
membrane potential, while a decrease in the red/green
fluorescence intensity ratio highlights mitochondrial
depolarization. Our analyses showed that mitochondria
were distributed broadly in the cytoplasm and charac-
terized by a perinuclear punctuated network in untreated
cells (Fig. 6b). Cells treated with 4-IPP showed mitochon-
dria with an altered morphology indicated by changes in
immunofluorescence staining patterns. Mitochondria ap-
peared much less tubular and a diffuse cytosolic pattern of
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showed signs of nuclear destruction (Fig. 6b, left). Metfor-
min treatment decreased the fluorescence of the probe and
several cells displayed a negative fluorescence signal (Fig. 6b,
right), indicating a clear loss of mitochondrial membrane
potential, which is an important indicator of functional
mitochondria. The results highlighted a mitochondrial
depolarization after metformin treatment (Fig. 6c).
Using electron microscopy to examine the morphology
of mitochondria in C2 organoids treated with 4-IPP, we ob-
served signs of necrosis, including strong condensation of
chromatin along a nuclear envelope. There, mitochondria
were smaller than in non-treated cells with significant im-
pairment of their structure. The number of lipid droplets in
cytosol was smaller than in cells treated with metformin
(Fig. 6D1-D3). In organoids treated with metformin, we
found many large mitochondria with irregular contours
and a modest number of cristae. These mitochondria con-
tained multi-lamellar structures inside, and were aligned
with residual lipid droplets accumulated inside the cytosol
(Fig. 6D4-D6).
These results suggested that ROS production likely
due to the loss/reduction of mitochondrial activity
affected viability of C2 organoids (Fig. 6e). Specifically,
4-IPP treated C2 organoids showed autophagy structures
(Fig. 6d) that are associated with necrosis and cell death.
4-IPP and metformin effects are recapitulated also in the
C1 organoids
To further evaluate the relevance of the results ob-
tained through 4-IPP and metformin, we assessed
whether 4-IPP and metformin could inhibit the MIF/
CD74 signalling axis and AMPK, respectively, by deter-
mining their effects on the expression of targets also in
C1 organoids. Treatments impaired the principal mor-
phological features of C1 organoids, leading to loss of
the spheroids organization (Fig. 7a and d). Western blot
analysis confirmed that 4-IPP at 50 and 100 μM in-
creased ERK-1/2 phosphorylation and down-regulated
AKT and AMPK activity (Fig. 7b). Moreover in C1
organoids, 5 mM metformin inhibited the mTOR path-
way, and downregulated AKT and ERK activity (Fig. 7e).
As shown in Fig. 7c, the anti-phosphotyrosine and anti-
phosphothreonine profiles of the 4-IPP-treated cells
presented a significant increase in phosphorylated pro-
teins profiles compared with control groups. In parallel,
we observed the change of PP2A phosphorylation sta-
tus indicating failed phosphatase activity (data not
shown). Trypan blue assay also displayed that 4-IPP
treatments at 50 and 100 μM, strongly impaired C1
organoids viability after twenty-four and forty-eight
hours. On the other hand, after one-hundred and
twenty hours, 5 mM metformin slightly affected C1 via-
bility (Fig. 7d). Taken together, these results confirmthe validity and reproducibility of treatments with 4-
IPP and metformin in colon-cancer carcinomatosis-
derived organoids.
Immunohistochemical expression of CD74 and MIF
was studied in three additional peritoneal CRC-pcs (C3,
C4 and C5), along with their corresponding normal
colon samples (Fig. 8). In normal colon samples, CD74
was widely and strongly expressed by both normal epi-
thelial cells and the surrounding reactive cell micro-
environment. The lymphocytes were strongly CD74
positive. The expression of CD74 in neoplastic tumour
cells was heterogeneous, ranging from strong cytoplas-
mic and membranous (samples C4 and C5) to weak
granular cytoplasmic (sample C3). MIF was poorly
expressed by normal epithelial cells. Conversely, all
tumour cells exhibited cytoplasmic and membranous
staining which ranged from weak to moderate and
strong.
Discussion
We explored the opportunity of using data from the secre-
tome analysis of patient-derived cancer organoids estab-
lished from two peritoneal carcinomatosis (C1 and C2), to
identify possible targets for therapy. The analysed orga-
noids presented self-renewal capacity, the ability to form
the typical 3D structure, and a significant positivity for
stem biomarkers, as shown by the number of highly-
dividing LGR5+ CSCs, especially in C2 organoids. LGR5+
cells are believed to be fast-cycling and resistant to irradi-
ation and chemotherapy and have been shown to initiate
intestinal organoid growth in a 3D culture system when
isolated from the mouse small intestine [8, 26]. This high
proliferation suggests that LGR5+ cells are adapted to fa-
cilitate the uptake and incorporation of nutrients into the
biomass (nucleotide, amino acids and lipids) needed to
generate new cells [27]. Remarkably, this adaptation is not
merely due to in vitro growth conditions but was a charac-
teristic already present in the original tumours, both pre-
senting a high number of LGR5+ cells and high mitotic
index.
Accordingly, GO Analysis of the secretome profile of
the fastest growing C2 organoids revealed prominent ex-
pression of metabolic pathways related to oxidative
homeostasis, glucose metabolism, and the major glucose
catabolic pathway (pentose phosphate pathway) that
links glucose metabolism to biosynthesis of the nucleo-
tide precursor ribose, coordinating glucose flux and sup-
porting the cellular biogenesis of macromolecules and
energy production [28].
The simultaneous positivity of the two organoids for
MIF suggests the rationale for inhibition of MIF/CD74
signalling axis, which is known to support AMPK activa-
tion, glycolysis, oxidative phosphorylation, but also to
compensate for the effects of high glucose oxidation
Fig. 7 4-IPP and metformin effects are recapitulated using C1 organoids. a Micrographs of C1 organoids before and after 4-IPP treatments. 4-IPP
treatment induced loss of the original spheroid organization. Magnifications: 10X. Scale bars = 50 μm. b Immunoblots of the principal proteins
involved in CD74/MIF signaling pathway. C1 organoids were untreated or treated with 50 and 100 μM 4-IPP for 24 h; lysates were resolved by
4–12% SDS–PAGE and immunoblotted. c Immunoblots showing the expression and activity of the α-pTyr and α-pThr proteins before and after
4-IPP treatment. C1 organoids were untreated or treated with 50 and 100 μM 4-IPP for 24 h; lysates were resolved by 4–12% SDS–PAGE and
immunoblotted. d C1 organoids were treated with 50 and 100 μM 4-IPP for 24 and 48 h. The percentage of cell death was determined by trypan
blue exclusion assay. Data are expressed as the mean ± SD. *P< 0.01 compared with untreated control and 50 μM 4-IPP. **P< 0.01 compared with
untreated control and 100 μM 4-IPP. All the experiments were replicated at least three times. e Micrographs of C1 organoids before and after metformin
treatments. Metformin treatment induced a moderate loss of the original spheroids organization. Magnifications: 10X. Scale bars = 50 μm. f Immunoblots
of the principal proteins involved in the metformin pathway. C1 organoids were treated with 5 mM metformin for 120 h; lysates were resolved by 4–12%
SDS–PAGE and immunoblotted. Images are representative of the results from at least two experiments. g C1 organoids were treated with 5 mM metformin
for 120 h. The percentage of cell death was determined by trypan blue exclusion assay. Data are expressed as the mean ± SD. We have not observed
significant increase in the percentage of cell death after metformin treatments compared with untreated controls. All the experiments were replicated at
least three times
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and translocation of Glut4 with a consequent increase in
glucose uptake, which in turn activates the PI3K/AKT
pathway [30]. Activated AMPK is also responsible for
initiating alternative energy-generating processes such as
fatty acid oxidation [31]. The activation of AMPK and
the subsequent glycolytic switch observed in mitotic
cells supports the possibility of a dependence on energy
pathways to survive in mitosis [32]. AMPK senses ATP
loss and enhances glycolysis to protect from death.Previous research has shown that MIF acts through the
AMPK signalling pathway to induce cellular resistance
to glucose deprivation, ischemia, hypoxia, oxidation and
stress senescence [22].
Our results support the concept that CSCs, through
the expression of MIF and CD74, become protected by
energy-default processes which force cancer cells with
defective mitochondria to generate energy through an
AMPK-regulated glycolysis in the cytoplasm [33]. Thus, the
inhibition of AMPK signalling through the suppression of
Fig. 8 CD74 and MIF IHC staining in three additional CRC-pc samples. In the upper part of the Figure, the normal colon mucosa from the three
patients is shown. In all the cases, CD74 is highly expressed in epithelial cells and in the surrounding normal cellular microenvironment. Conversely,
MIF is poorly expressed. MIF staining is mainly restricted to epithelial cells. In the lower part of the figure, the corresponding peritoneal carcinomatoses
(C3, C4 and C5) are shown. Immunohistochemical staining for CD74 is heterogeneous with a granular, cytoplasmic and membranous pattern in C3,
while focal, granular and restricted to the inner luminal aspect in C4 (inset) and C5. MIF immunostaining is homogeneous and very low expressed in
C3 compared to C4 and C5. MIF staining is mainly cytoplasmic. Images were taken using a Nikon Eclipse 80i microscope (Nikon, Tokyo, Japan) and
Nikon digital sight DS-Fi1 camera equipped with control unit-DS-L2 (Nikon). Images were assembled using Adobe Photoshop 6 (Adobe Systems, San
Jose, CA, USA). Original magnification at 20X
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fects the special energetic requirements of C1 and C2
organoids.
Indeed, knocking down MIF/CD74 signalling through
4-IPP decreased SOD1 and resulted in changes in mito-
chondrial morphology and mass. An increase of ROS
produced a JNK mediated stress response (Fig. 4). The
oxidative shift in the redox conditions reduced phospha-
tases activity, blocking signal propagation in the cell
through a number of signalling pathways involving pro-
tein kinases [34].
In both organoids, the inhibition of AMPK-mediated
signalling is associated with the inactivation of both
AKT and FOXO3. Of note, FOXO3 can induce a num-
ber of genes that protect against ROS suggesting that it
plays a role in keeping cellular ROS low. JNK activation
resulted after treatment, possibly modulating cellular re-
sponse to ROS independent of changes in the intracellular
AMP level [7] and likely inducing a defective autophagic
process followed by rapid cell death.
ROS increase is also the cause of the observed inacti-
vation of PP2A phosphatase and of the relevant conse-
quences in terms of signal transduction response.
Inhibition of ERK1/2 dephosphorylation and the general
inhibition of protein dephosphorylation observed after
treatment support this interpretation of the results.
However, redox regulation of phosphatases is poorly
understood. Protein phosphatases are inhibited by ROS,
which target specific redox sensitive amino acids, but
PP2A catalytic activity leading to the activation of cellu-
lar stress signalling pathways can be also modulated by
hydrogen peroxide [35].Our findings define a MIF/CD74/AMPK pathway in
the colon peritoneal carcinomatosis, for the first time
elucidating a signal transduction mechanism between
autocrine/paracrine factors and AMPK activation. The
results provide initial proof-of-concept that pharmaco-
logic treatment blocking MIF/CD74 signalling pathways
disrupts energy homeostasis in CRC-pc derived orga-
noids, in vitro, by inducing cell death.
Our investigations were also aimed to study the effects
of metformin, a drug for treating type 2 diabetes, whose
use has been associated with decreased cancer risk, and
that kills cancer-initiating/stem cells from a variety of
cancers with AMPK activation [25]. Metformin is known
to inhibit the mitochondrial respiratory chain complex I
that reduces ATP production and increases the intracel-
lular ratio of AMP/ATP, resulting in AMPK activation
that switches cells from an anabolic to a catabolic state.
We found that metformin reprograms organoid metab-
olism. This process involved both AMPK activation,
which reduces mTOR activity and protein translation,
and complex I inhibition, which promotes ROS produc-
tion within the mitochondrial matrix. As an effect of
AMPK activation, glycolysis was stimulated, producing a
large amount of lactate. Furthermore, the inhibition of
complex I promoted superoxide production within the
mitochondrial matrix, which provoked dysfunctional
mitochondrial swelling, interrupted the tricarboxylic acid
cycle and led to a compensatory increase in lactate and
glycolytic ATP and aberrant lipid accumulation.
C2 organoids treated with metformin presented dra-
matic changes in mitochondria morphology – deform-
ation and partial loss of mitochondrial membranes and
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mulation of free radicals and loss of membrane poten-
tial. These effects could be explained by the ability of
metformin to induce mitochondrial depolarization and in-
crease ROS through inhibition of complex I [36], which
also leads to mitochondrial cristae degradation [37]. Loss of
mitochondrial function limits the production of lipids, nu-
cleotides and amino acids used by cells for the creation of
new biomass, and could explain the inhibited cell prolifera-
tion after treatment with metformin, as suggested by the
reduced number of disaggregated cells counted in treated
samples during the trypan blue assay (data not shown).
In conclusion, 4-IPP and metformin have profound
effects on the metabolism of organoids derived from
CRC-pcs. Interestingly, C1 and C2 organoids presented
different phenotypic features, but similar responses
when treated with 4-IPP or metformin – activation of
stress-signalling pathways and cell death with 4-IPP
treatments; inhibition of mitochondria, oxidation of glu-
cose and lipids resulting in energy restriction with met-
formin treatments.
We have previously shown that inhibition of MIF/
CD74 signalling axis blocks thyroid cancer cells growth
by inducing cell death during mitosis [24]. Other studies
have demonstrated the efficacy of MIF or CD74 target-
ing in several cancers providing a rationale for the devel-
opment of therapeutic agents and clinical trials to study
the effects of inhibiting a newly discovered MIF isoform
(oxMIF) on different cancers, including metastatic CRC
(NCT01765790). Milatuzumab, the first anti-CD74 anti-
body that has entered into clinical tests, is currently
being studied for the treatment of non Hodgkin lymph-
omas, chronic lymphocytic leukemia, and multiple mye-
loma [33, 38] and could be potentially tested in MIF/
CD74 positive CRC-pc.
MIF inhibitors, particularly when acting on the MIF/
CD74 axis, could be a very attractive strategy for cancer
therapeutic intervention due to the nonphysiologic
enzymatic activity of the cytokine that is evolutionary
well-conserved [39]. MIF belongs to the family of tauto-
merase proteins and can catalyze the tautomerization of
nonphysiologic substrates, such as D-dopachrome and
L-dopachrome methyl ester, into their corresponding
indole derivates. This peculiar feature seems to be medi-
ated by the NH2-terminal Proline of MIF (Pro-1) and
strategies based on targeting Pro-1 are able to abrogate
the tautomerase activity [40]. Indeed, different works
have shown that the development of small molecules an-
tagonist of the MIF enzymatic active site could be an ef-
fective strategy to abrogate its functions. Winner and
colleagues showed how 4-IPP serves as suicide substrate
for MIF, resulting in the covalent modification of Pro-1
[41]. Exposure to 4-IPP decreased MIF immunoreactivity
and similar results were also recapitulated using MIFsilencing-based strategies [42]. Some recent works
showed how 4-IPP interferes with several activities pecu-
liar of MIF, such as neutrophil lung recruitment [43], the
maintenance of a chemoresistant phenotype [44] and the
reprogramming of tumor associated macrophages that
supports malignant plasma cell survival and resistance
to therapy in multiple myeloma cells [45].
Moreover, MIF inhibitors, particularly in conjunction
with CD74 inhibition, could be very efficient in blocking
CRC-pc progression. The systemic effects of inhibitors
that interfere with energy metabolism are still only par-
tially known, however ongoing clinical studies seem to
give encouraging results.
Differently, metformin is widely used with mild or no
side effects, and therefore the effects of energetic reduc-
tion induced by metformin on organoids could be com-
bined with drugs which can act in synergy and induce
cell death.
Conclusions
Our study shows that the modulation of AMPK function,
both through its activation by metformin, or its reduction
caused by the removal of MIF/CD74 signalling axis, is crit-
ical for maintaining cell energy balance of CRC-pc. Metfor-
min elicits the metabolic reprogramming by decreasing
oxidative phosphorylation and increasing dependency on
glycolytic metabolism. Conversely, inhibition of MIF/CD74
signalling axis elevated ROS rendering cancer cells vulner-
able to oxidative stress-induced cell death. In conclusion,
targeting the metabolism of cancer cells opens new lines of
research that could lead to the design of new therapies for
the treatment of CRC-pc.
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